NEXCCS

NexCCS is the most advanced and validated embryo screening platform available for in vitro fertilization (IVF) today.

Validated over several years and many rigorous clinical trials, NexCCS can accurately and comprehensively determine if an embryo possesses the right number of chromosomes (euploidy) or too few or too many (aneuploidy). Published data suggests that 50-70% of miscarriages are due to embryos with too few or too many chromosomes.

NexCCS is owned and operated by the Foundation for Embryonic Competence. All proceeds from NexCCS testing go directly to the FEC and are used to support research and education. Learn more about the Foundation at FECLABS.org.

FEATURES OF THE NEXCCS PROCESS:

• Greater than 98% accuracy¹
• Day 5 biopsy, safest method for any PGD testing²
• 4% delivery rate in a recent clinical trial²

ONE HEALTHY EMBRYO, ONE HEALTHY BABY

The transfer of two or more embryos often results in high-risk and complicated pregnancies and deliveries more than 30% of the time in the U.S. Utilizing NexCCS to choose the single best embryo for transfer makes  the promise of Single Embryo Transfer (SET) a reality and provides a safer and more effective treatment option for many patients.

UNCOMPROMISED RESULTS

• High singleton success rates demonstrated in RMANJ’s BEST (Blastocyst Euploid Selective Transfer) Trial.³

FEWER COMPLICATIONS

• Combining NexCCS and SET can reduce the risks of miscarriage and complications associated with multiple deliveries.

Learn more about Single Embryo Transfer (SET).